Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Arsanis logo — Leading the fight against infectious diseases with advanced...

Arsanis

Leading the fight against infectious diseases with advanced monoclonal antibody therapies.

Founded 2010 11-50 employees Post-IPO Equity Total: $120.26M Biotechnology, Health Care +1

General Information

Company Name Arsanis
Founded Year 2010
Employees 11-50
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Arsanis. To contact Arsanis, visit arsanis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arsanis compare?

A PDF of Arsanis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arsanis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arsanis

Arsanis is a clinical-stage biopharmaceutical company founded in 2010 that focuses on developing monoclonal antibody (mAb) immunotherapies to combat serious infectious diseases. The company's lead clinical program, ASN100, targets Staphylococcus aureus infections and is currently in Phase 2 clinical trials. Arsanis has an extensive preclinical pipeline including mAbs against various bacterial and viral pathogens such as the respiratory syncytial virus. The company's extensive knowledge of infection pathogenesis, along with access to advanced mAb discovery techniques and platforms, positions Arsanis as a strong player in the biotechnology, health care, and life sciences industries. With its operations based in Waltham, Massachusetts, and its European research and preclinical development operations located in Vienna, Austria through Arsanis Biosciences GmbH, the company benefits from a geographically diverse presence. In December 2017, Arsanis received a $20.00M post-IPO equity investment, emphasizing investor confidence in the company's potential to advance the development of novel mAbs for infectious disease treatment. With its advancing pipeline of mAbs with multiple mechanisms of action and high potency, Arsanis holds promise in leading the fight against infectious diseases, making it an intriguing prospect for venture capital and investment.

Business keywords: biopharmaceuticals, monoclonal antibodies, infectious diseases, clinical-stage, immunotherapies, mAb discovery, Staphylococcus aureus, Phase 2 clinical trial, preclinical pipeline, antibacterial therapies, viral pathogens, respiratory syncytial virus, Waltham, Massachusetts, Vienna, Austria, pathogenesis of infection

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $20.00M -
04 Dec 2017
Series D $45.50M 7
GV Polaris Partners SV Health Investors
GV, Polaris Partners +5
26 Apr 2017
Grant $9.30M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
27 Feb 2017
Series C $15.01M 1
SV Health Investors
SV Health Investors
27 Apr 2016
Debt Financing Undisclosed 1
SV Health Investors
SV Health Investors
12 Apr 2016
Grant €50.00K 1
EASME - EU Executive Agency for SMEs
01 Oct 2014
Series B $20.00M 4
Polaris Partners SV Health Investors OrbiMed
Polaris Partners, SV Health Investors +2
03 Sep 2013
Series A $10.00M 3
Polaris Partners SV Health Investors OrbiMed
Polaris Partners, SV Health Investors +1
28 Feb 2011
Venture Round $400.00K -
22 Sep 2010

Arsanis Alternatives & Competitors

Arsanis vs
Vigil Neuroscience
Vigil Neuroscience United States

Harnessing the power of microglia to transform treatments for neurodegenerative diseases

Acquired
76 employees
Biotechnology, Health Care

FAQ About Arsanis

Leading the fight against infectious diseases with advanced monoclonal antibody therapies.
Arsanis was founded in 2010.
Arsanis operates in Biotechnology, Health Care and Life Sciences. Its work centres on biopharmaceuticals, monoclonal antibodies, infectious diseases and clinical-stage.
Arsanis has approximately 11-50 employees.
Arsanis has completed 9 funding rounds, raising a total of $120.26M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Arsanis include Vigil Neuroscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arsanis and Vigil Neuroscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arsanis, https://bouncewatch.com/company/arsanis, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes